Bayer's Xarelto to join Pradaxa for NICE stroke prevention
This article was originally published in Scrip
Executive Summary
Bayer has managed to convince NICE, the health technology appraisal institute for England and Wales, to recommend its oral anticoagulant Xarelto (rivaroxaban) for preventing stroke and systemic embolism in atrial fibrillation patients.